BioPharmSignal logoBioPharmSignal

Biotech News

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.2026-06-25 13:46 ESTClinical readout

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy

Open original release

Related news

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Participate in Upcoming Investor Conferences

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-25 13:46 EST

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

View all latest news

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

OLMAOlema Pharmaceuticals, Inc.2026-06-26 10:03 EST

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

OLMAOlema Pharmaceuticals, Inc.2026-06-26 10:03 EST

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OLMAOlema Pharmaceuticals, Inc.2026-06-26 10:03 EST

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-06-26 10:03 EST

Olema Oncology to Participate in Upcoming Investor Conferences

OLMAOlema Pharmaceuticals, Inc.2026-06-26 10:03 EST

Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States